Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ardelyx Inc
(NQ:
ARDX
)
6.180
+0.050 (+0.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ardelyx Inc
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, Ardelyx, Symbotic, and Five Below and Encourages Investors to Contact the Firm
August 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
August 29, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
August 28, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
What 6 Analyst Ratings Have To Say About Ardelyx
August 02, 2024
Via
Benzinga
Analyst Expectations For Ardelyx's Future
June 20, 2024
Via
Benzinga
How Is The Market Feeling About Ardelyx?
June 04, 2024
Via
Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, Ardelyx, Symbotic, and Five Below and Encourages Investors to Contact the Firm
August 26, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ARDX Class Action Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ardelyx, Inc. Class Action
August 26, 2024
From
Robbins LLP
Via
GlobeNewswire
ARDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ardelyx, Inc. Investors Can Join the Class Action Lawsuit!
August 23, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
What Analysts Are Saying About Ardelyx Stock
May 24, 2024
Via
Benzinga
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 21, 2024
From
Schall Law
Via
GlobeNewswire
ARDELYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. and Encourages Investors to Contact the Firm
August 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Ardelyx, Inc. Investor Notice: Robbins LLP Reminds Shareholders of the Pending ARDX Class Action
August 20, 2024
From
Robbins LLP
Via
Business Wire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 19, 2024
From
The Schall Law Firm
Via
Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
August 19, 2024
From
Faruqi & Faruqi, LLP
Via
Business Wire
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
August 19, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Stockholder Alert: Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action Against ARDX
August 18, 2024
From
Robbins LLP
Via
GlobeNewswire
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
August 08, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
August 01, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
July 31, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Get Your Money Out of These 3 Biotech Stocks Before the End of July
July 28, 2024
These stocks are at a risk of providing negative returns to shareholders due to the several operational challenges faced by the companies.
Via
InvestorPlace
Ardelyx Files Lawsuit Over Medicare Drug Payment Rules, Claims It Will Limit Patient Access To Kidney Disease Treatment
July 18, 2024
Ardelyx challenges CMS in a lawsuit over Medicare's inclusion of Xphozah in bundled payments, affecting kidney disease drug accessibility.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
July 18, 2024
Conference call scheduled for 4:30 p.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
July 17, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Why Ardelyx Stock Is Dropping
July 02, 2024
Ardelyx shares are trading lower Tuesday after the company announced it has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services End-Stage Renal Disease (ESRD)...
Via
Benzinga
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
July 02, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
June 28, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
3 Stocks Under $10 With the Potential to Make You a Millionaire
June 16, 2024
Looking for volume plays? Here are three stocks under $10 that might just drive your earnings to millions in the next few years.
Via
InvestorPlace
Ardelyx, Inc. Reports Employment Inducement Grants
May 30, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
May 30, 2024
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.